Valuation: Bolt Biotherapeutics, Inc.

Market Cap 7.67M 6.64M 6.27M 5.69M 10.67M 735M 10.75M 74.87M 28.85M 373M 28.8M 28.16M 1.19B P/E 2026 *
-0.17x
P/E 2027 * -0.2x
Enterprise Value 7.67M 6.64M 6.27M 5.69M 10.67M 735M 10.75M 74.87M 28.85M 373M 28.8M 28.16M 1.19B EV / Sales 2026 *
38.3x
EV / Sales 2027 * 2.19x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+0.76%
1 week+2.05%
1 month+18.81%
3 months-12.72%
6 months+1.79%
Current year-27.21%
1 week 3.25
Extreme 3.25
4.09
1 month 3.15
Extreme 3.15
4.27
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
331.4
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 14/05/2024
Chief Executive Officer 55 14/05/2024
Chief Operating Officer 61 14/05/2024
Director TitleAgeSince
Director/Board Member 64 30/11/2020
Director/Board Member 55 14/05/2024
Chairman 56 03/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
10/06/26 Free

Chairman

5,000 0.2602%
28/01/26 Free

Chief Operating Officer

10,000 0.5210%
28/01/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%+2.05%-23.15%-84.69% 7.61M
+5.04%+3.66%+50.62%+103.77% 66.93B
+1.64%-0.18%+34.67%+76.81% 61.97B
-3.18%-0.78%-14.14%+369.82% 28.26B
+0.33%0.00%+26.93%+12.30% 24.59B
+2.20%-4.72%+2.19%-13.14% 24.3B
+1.15%-1.17%+17.56%-21.92% 19.41B
-7.03%-10.19%+161.91%+303.00% 16.77B
-2.29%-3.65%-7.62%+495.19% 14.18B
+4.96%+4.63%-2.75%+864.40% 14B
Average +0.36%-2.83%+24.62%+210.55% 27.04B
Weighted average by Cap. +1.30%-1.95%+32.40%+169.81%

Financials

2026 *2027 *
Net sales 200K 173K 164K 148K 278K 19.17M 280K 1.95M 753K 9.72M 751K 735K 30.92M 3.5M 3.03M 2.86M 2.6M 4.87M 335M 4.91M 34.18M 13.17M 170M 13.15M 12.86M 541M
Net income -47.4M -41.07M -38.76M -35.16M -65.96M -4.54B -66.44M -463M -178M -2.3B -178M -174M -7.33B -47.5M -41.16M -38.84M -35.24M -66.1M -4.55B -66.58M -464M -179M -2.31B -178M -174M -7.34B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
14/09/26 US$3.980 +0.76% 19,634
11/09/26 US$3.950 +5.90% 77,076
10/09/26 US$3.730 +1.41% 96,974
09/09/26 US$3.678 -4.71% 4,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.980USD
Average target price
29.00USD
Spread / Average Target
+628.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!